BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Acusphere Inc. (ACUS) Appoints Mark Leuchtenberger as President and CEO


9/17/2013 7:43:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)-- Acusphere, Inc. (ACUSD.PK) today announced that Mark Leuchtenberger has been appointed President, Chief Executive Officer and a Director of the company, succeeding co-founder Sherri C. Oberg, who will remain on Acusphere’s Board of Directors as Vice Chairman. Acusphere is currently focused on the development and regulatory approval of Imagify™ (Perflubutane Polymer Microspheres) lyophilisate for dispersion for injection, a cardiovascular drug for the detection of coronary artery disease (CAD), the leading cause of death in the United States and Europe.

“I am thrilled to join Acusphere at what I believe is an exciting time in the company’s history,” said Mr. Leuchtenberger. “I look forward to working with the Acusphere team to complete the final stages of Imagify’s clinical evaluation and bringing this program forward to market.”

Martyn Greenacre, chairman of Acusphere’s board of directors, said, “We are delighted to attract an executive of Mark’s caliber and experience to lead Acusphere through its next phase of growth and development. We are indebted to Sherri for her dedication and years of success in shepherding Acusphere’s technology, including Imagify as its lead product candidate, to this pivotal point. Under Mark’s leadership, we are eager to move ahead with the exciting opportunities that we believe are available for Acusphere and Imagify.”

Mr. Leuchtenberger most recently served as President, Chief Executive Officer and a member of the board of directors at Rib-X Pharmaceuticals, bringing experience in commercial operations, business development and preparing biopharmaceutical companies for product approval and commercialization. Prior to joining Rib-X, Mr. Leuchtenberger served as President and Chief Executive Officer of Targanta Therapeutics Corporation, where he led the company’s initial public offering in 2007 and its acquisition in 2009. Mr. Leuchtenberger served as the President and Chief Executive Officer of Therion Biologics Corporation, a privately held cancer vaccine company. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Idec Inc., where he led the Avonex® development and launch in the United States and subsequently managed North American and international commercial operations. Mr. Leuchtenberger received his M.B.A. from the Yale School of Management and his B.A. from Wake Forest University. He is a director and past chairman of the Massachusetts Biotechnology Council Board of Directors and currently serves as a trustee for Beth Israel Deaconess Medical Center. He is a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc.

Added Ms. Oberg, “I share the Board’s genuine excitement and enthusiasm in welcoming Mark to Acusphere. His exceptional capabilities and expertise, particularly in leading one of the most successful product launches in biotech history with Avonex, will be critical in driving forward the commercialization opportunities for Imagify in the years ahead.”

About Acusphere, Inc.

Acusphere, Inc. (ACUSD.PK) is a specialty pharmaceutical company focused on the development and regulatory approval of our lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) lyophilisate for dispersion for injection. Imagify is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States and Europe. Imagify was created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles, which were customized to control the delivery of gas needed for ultrasound myocardial perfusion assessment. For more information about Acusphere visit the Company's web site (www.acusphere.com).

Contact:

MacDougall Biomedical Communications

Douglas MacDougall, 781-235-3060

or

Bianca Nery, 650-339-7533

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES